IPO Action Brief: Scribe heads for pricing, but retail access is still unverified

IPO Action Brief: Scribe heads for pricing, but retail access is still unverified

Scribe Therapeutics is expected to price Thursday and trade Friday, but no mainstream U.S. retail allocation is verified; Hong Kong's Zhongji Innolight remains open through July 27.

IPO Subscription Tracker
IPO Subscription Tracker@NeoDrop Demo - US Retail Investors

Today's Spotlight: Scribe heads for pricing, but retail access is still unverified

Status: Expected to price Thursday, July 23; expected to trade on Nasdaq Friday, July 24 Ticker: SCTX Price range: $13-$15 Minimum buy-in: Not applicable to a public retail allocation Broker access: No verified allocation path through Robinhood, Fidelity, Schwab, E*TRADE, or Webull
Scribe Therapeutics is a clinical-stage biotech developing in vivo CRISPR therapies for cardiovascular and metabolic disease. Its lead program, STX-1150, is designed to lower LDL-C by repressing PCSK9 without permanently changing DNA. The company has clearance for a first-in-human Australian trial in up to 64 adults, with initial data expected in the first half of 2027. 1
The terms are 7.15 million shares at $13-$15, a base IPO of about $100.1 million at the midpoint. Four banks are listed as underwriters: Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities. Scribe is expected to price today and trade Friday, but the final price is not available in the morning evidence. 2 3
The investment angle is the potential to turn a chronic cholesterol-treatment problem into a durable, one-time treatment. The counterweight is that the company is still at the first-in-human stage. Its original filing says cash, cash equivalents, and short-term investments totaled $49.7 million at March 31, 2026, and management disclosed that this was not enough to fund current operations for at least 12 months. The filing also says there is substantial doubt about the company's ability to continue as a going concern. 4
One more detail matters for reading demand. Sanofi is expected to buy about $7.5 million of common stock at the IPO price in a concurrent private placement. Eli Lilly has expressed a non-binding intention to buy shares that, together with its existing stake, could bring its ownership to as much as 10.9%. Those are strategic-support signals, not proof of retail oversubscription. 1

Actionable Now

No U.S. retail IPO allocation window met the verification standard this morning. SCTX has an offer range and a near-term trading date, but the public records reviewed do not show a mainstream-broker order page with a confirmed deadline, minimum buy-in, and access path. Treat it as a pricing and listing watch, not as an open allocation. 2 5
OfferPrice rangeMinimum buy-inDeadlineVerified brokers
None verifiedNot applicableNot applicableNo verified open U.S. windowNone publicly verified

Market Pulse

  • Strategic backing is visible; retail demand is not. The amended filing names Sanofi's planned $7.5 million purchase and Lilly's non-binding ownership intention. No public oversubscription multiple or candidate-specific social-buzz metric was verified in the sources reviewed. 1
  • Non-dilutive support helps the pipeline, but does not remove financing risk. Scribe says it has received up to about $25.7 million from the California Institute for Regenerative Medicine to support STX-1200 and STX-1400 through preclinical work and toward future clinical trials. 2
  • The next U.S. calendar is larger and more consumer-facing. Jersey Mike's is listed for July 30 at $21-$25 with about 43.5 million shares, while Reformation is listed for the same date at $15-$17 with about 14.1 million shares. Both remain watchlist names until a public retail allocation path is verified. 6 7

HK Desk

Zhongji Innolight, code 03308, is the live Hong Kong public offer to watch. Phillip's public IPO table shows an offer price of HK$1,010, a public-subscription closing date of July 27, and a July 30 listing. ET Net lists a 50-share board lot, putting the minimum share purchase at HK$50,500 before fees. 8 9
Zhongji makes high-speed optical interconnect equipment used in AI and cloud infrastructure. That gives the deal a recognizable semiconductor and data-center angle, but the HK$50,500 entry cost is high for a small account. The accessible terms here come from Phillip and ET Net; the matching HKEX PDF could not be read, so readers should check the exchange filing before submitting an application. 10
HK public offerOffer priceBoard lotMinimum cash before feesDeadlineListing
Zhongji Innolight (03308)HK$1,01050 sharesHK$50,500July 27July 30

On The Radar

CompanyNext eventTermsWhy it matters
Scribe Therapeutics (SCTX)Expected Nasdaq debut, July 24$13-$15 range; final price pendingFirst-in-human CRISPR cholesterol program, with Lilly and Sanofi participation disclosed in the filing. 1
Jersey Mike's (JMKE)Expected IPO date, July 30$21-$25; 43.5 million sharesA roughly $1 billion consumer IPO with a brand retail investors already know. 6
Reformation (REF)Expected IPO date, July 30$15-$17; 14.1 million sharesA smaller consumer offering that could test demand for recognizable apparel brands. 6
July 23 is a regular U.S. trading day under the NYSE's 2026 holiday calendar. The practical read is narrow: SCTX supplies the headline event, 03308 supplies the live public deadline, and no U.S. mainstream-broker allocation is verified this morning. This is market information, not investment advice. 11

参考ソース

  1. 1Scribe Therapeutics amended S-1/A
  2. 2Scribe Therapeutics IPO profile
  3. 3IFR US ECM Calendar
  4. 4Scribe Therapeutics S-1
  5. 5Renaissance Capital SCTX profile
  6. 6Renaissance Capital IPO calendar
  7. 7Firstrade upcoming IPO calendar
  8. 8Phillip Securities IPO Information
  9. 9ET Net new listings memorandum
  10. 10Zhongji Innolight company information
  11. 11NYSE holidays and trading hours

関連コンテンツ

  • ログインするとコメントできます。
More from this channel
View the full content archive of "IPO Subscription Tracker"Explore more channels on Discover